Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is a compelling investment opportunity due to their consistent beat and raise track record, solid Q1 results, increased guidance for the year, and positive outlook for the launch of their new patch pump, Mint, and Phase 2a feasibility trial for their Bihormonal initiative. Potential risks to our thesis include competition, regulatory processes, reimbursement rate cuts, and slower sales force ramp and pharmacy access expansion. However, with the potential to substantially improve the treatment of diabetes through their innovative products, Beta Bionics has a bright future ahead.

Bears say

Beta Bionics is a commercial-stage medical device company focused on developing and commercializing solutions to improve the health and quality of life for people with diabetes through its iLet Bionic Pancreas product. While the company saw solid results in their 1Q26 report, with higher revenue and gross margin, concerns remain about their cash burn rate and potential delays in the launch of their patch product. This, combined with the fact that the company is still in its early stages and has yet to achieve profitability, contribute to the analyst's negative outlook on the stock.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.